# Hong Shen

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8227452/publications.pdf

Version: 2024-02-01

| 43 | 1,388 | 331259 21 | 344852 36 |
|---|---|---|---|
| papers | citations | h-index | g-index |

| 43 | 43 | 43 | 747 |
|---|---|---|---|
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Clinical Probes and Endogenous Biomarkers as Substrates for Transporter Drugâ€Drug Interaction Evaluation: Perspectives From the International Transporter Consortium. Clinical Pharmacology and Therapeutics, 2018, 104, 836-864. | 2.3 | 141 |
| 2 | Coproporphyrins in Plasma and Urine Can Be Appropriate Clinical Biomarkers to Recapitulate Drug-Drug Interactions Mediated by Organic Anion Transporting Polypeptide Inhibition. Journal of Pharmacology and Experimental Therapeutics, 2016, 358, 397-404. | 1.3 | 132 |
| 3 | Coproporphyrins I and III as Functional Markers of OATP1B Activity: In Vitro and In Vivo Evaluation in Preclinical Species. Journal of Pharmacology and Experimental Therapeutics, 2016, 357, 382-393. | 1.3 | 88 |
| 4 | Cynomolgus Monkey as a Potential Model to Assess Drug Interactions Involving Hepatic Organic Anion Transporting Polypeptides: In Vitro, In Vivo, and In Vitro-to-In Vivo Extrapolation. Journal of Pharmacology and Experimental Therapeutics, 2013, 344, 673-685. | 1.3 | 73 |
| 5 | Characterization of Organic Anion Transporter 2 (SLC22A7): A Highly Efficient Transporter for Creatinine and Species-Dependent Renal Tubular Expression. Drug Metabolism and Disposition, 2015, 43, 984-993. | 1.7 | 73 |
| 6 | Comparative Evaluation of Plasma Bile Acids, Dehydroepiandrosterone Sulfate, Hexadecanedioate, and Tetradecanedioate with Coproporphyrins I and III as Markers of OATP Inhibition in Healthy Subjects. Drug Metabolism and Disposition, 2017, 45, 908-919. | 1.7 | 67 |
| 7 | Organic Anion Transporter 2: An Enigmatic Human Solute Carrier. Drug Metabolism and Disposition, 2017, 45, 228-236. | 1.7 | 62 |
| 8 | Gaining Mechanistic Insight Into Coproporphyrin I as Endogenous Biomarker for OATP1Bâ€Mediated Drugâ€“Drug Interactions Using Population Pharmacokinetic Modeling and Simulation. Clinical Pharmacology and Therapeutics, 2018, 104, 564-574. | 2.3 | 56 |
| 9 | Organic Anion Transporter Polypeptide 1B1 Polymorphism Modulates the Extent of Drugâ€“Drug Interaction and Associated Biomarker Levels in Healthy Volunteers. Clinical and Translational Science, 2019, 12, 388-399. | 1.5 | 53 |
| 10 | Assessment of Vandetanib as an Inhibitor of Various Human Renal Transporters: Inhibition of Multidrug and Toxin Extrusion as a Possible Mechanism Leading to Decreased Cisplatin and Creatinine Clearance. Drug Metabolism and Disposition, 2013, 41, 2095-2103. | 1.7 | 49 |
| 11 | Further Studies to Support the Use of Coproporphyrin I and III as Novel Clinical Biomarkers for Evaluating the Potential for Organic Anion Transporting Polypeptide 1B1 and OATP1B3 Inhibition. Drug Metabolism and Disposition, 2018, 46, 1075-1082. | 1.7 | 44 |
| 12 | Discovery and Validation of Pyridoxic Acid and Homovanillic Acid as Novel Endogenous Plasma Biomarkers of Organic Anion Transporter (OAT) 1 and OAT3 in Cynomolgus Monkeys. Drug Metabolism and Disposition, 2018, 46, 178-188. | 1.7 | 40 |
| 13 | Evidence for the Validity of Pyridoxic Acid (PDA) as a Plasma-Based Endogenous Probe for OAT1 and OAT3 Function in Healthy Subjects. Journal of Pharmacology and Experimental Therapeutics, 2019, 368, 136-145. | 1.3 | 38 |
| 14 | Comprehensive Evaluation of the Utility of 20 Endogenous Molecules as Biomarkers of OATP1B Inhibition Compared with Rosuvastatin and Coproporphyrin I. Journal of Pharmacology and Experimental Therapeutics, 2019, 368, 125-135. | 1.3 | 36 |
| 15 | Induction of Human Intestinal and Hepatic Organic Anion Transporting Polypeptides: Where Is the Evidence for Its Relevance in Drug-Drug Interactions?. Drug Metabolism and Disposition, 2020, 48, 205-216. | 1.7 | 36 |
| 16 | Evaluation of Rosuvastatin as an Organic Anion Transporting Polypeptide (OATP) Probe Substrate: In Vitro Transport and In Vivo Disposition in Cynomolgus Monkeys. Journal of Pharmacology and Experimental Therapeutics, 2015, 353, 380-391. | 1.3 | 31 |
| 17 | Endogenous Biomarkers to Assess Drug-Drug Interactions by Drug Transporters and Enzymes. Current Drug Metabolism, 2017, 18, 757-768. | 0.7 | 29 |
| 18 | Cynomolgus Monkey as a Clinically Relevant Model to Study Transport Involving Renal Organic Cation Transporters: In Vitro and In Vivo Evaluation. Drug Metabolism and Disposition, 2016, 44, 238-249. | 1.7 | 28 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Dissecting the Contribution of OATP1B1 to Hepatic Uptake of Statins Using the OATP1B1 Selective Inhibitor Estropipate. Molecular Pharmaceutics, 2019, 16, 2342-2353. | 2.3 | 27 |
| 20 | Recent advances in the translation of drug metabolism and pharmacokinetics science for drug discovery and development. Acta Pharmaceutica Sinica B, 2022, 12, 2751-2777. | 5.7 | 27 |
| 21 | Transporters in Drug Development: International Transporter Consortium Update on Emerging Transporters of Clinical Importance. Clinical Pharmacology and Therapeutics, 2022, 112, 485-500. | 2.3 | 27 |
| 22 | Rosuvastatin Liver Partitioning in Cynomolgus Monkeys: Measurement In Vivo and Prediction Using In Vitro Monkey Hepatocyte Uptake. Drug Metabolism and Disposition, 2015, 43, 1788-1794. | 1.7 | 21 |
| 23 | Detection of Weak Organic Anionâ€“Transporting Polypeptide 1B Inhibition by Probenecid with Plasma-Based Coproporphyrin in Humans. Drug Metabolism and Disposition, 2020, 48, 841-848. | 1.7 | 21 |
| 24 | PBPK Model of Coproporphyrin I: Evaluation of the Impact of SLCO1B1 Genotype, Ethnicity, and Sex on its Interâ€Individual Variability. CPT: Pharmacometrics and Systems Pharmacology, 2021, 10, 137-147. | 1.3 | 21 |
| 25 | UHPLCâ€“MS/MS bioanalysis of human plasma coproporphyrins as potential biomarkers for organic anion-transporting polypeptide-mediated drug interactions. Bioanalysis, 2018, 10, 633-644. | 0.6 | 14 |
| 26 | Cynomolgus Monkey as an Emerging Animal Model to Study Drug Transporters: In Vitro, In Vivo, In Vitro-to-In Vivo Translation. Drug Metabolism and Disposition, 2022, 50, 299-319. | 1.7 | 14 |
| 27 | Tissue distribution and tumor uptake of folate receptorâ€“targeted epothilone folate conjugate, BMS-753493, in CD2F1 mice after systemic administration. Acta Pharmaceutica Sinica B, 2016, 6, 460-467. | 5.7 | 13 |
| 28 | Physiologically Based Pharmacokinetic Modeling of Transporter-Mediated Hepatic Clearance and Liver Partitioning of OATP and OCT Substrates in Cynomolgus Monkeys. AAPS Journal, 2017, 19, 1878-1889. | 2.2 | 13 |
| 29 | Enhanced and Persistent Inhibition of Organic Cation Transporter 1 Activity by Preincubation of Cyclosporine A. Drug Metabolism and Disposition, 2019, 47, 1352-1360. | 1.7 | 13 |
| 30 | Xenobiotic Transporters in the Kidney: Function and Role in Toxicity. Seminars in Nephrology, 2019, 39, 159-175. | 0.6 | 13 |
| 31 | Triphenylethanamine Derivatives as Cholesteryl Ester Transfer Protein Inhibitors: Discovery of N-[(1R)-1-(3-Cyclopropoxy-4-fluorophenyl)-1-[3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl]-2-phenylethyl]-4-fluoro-3-(tri (BMS-795311). Journal of Medicinal Chemistry, 2015, 58, 9010-9026. | 2.9 | 11 |
| 32 | Renal Excretion of Dabigatran: The Potential Role of Multidrug and Toxin Extrusion (MATE) Proteins. Molecular Pharmaceutics, 2019, 16, 4065-4076. | 2.3 | 10 |
| 33 | Transporter Activity Changes in Nonalcoholic Steatohepatitis: Assessment with Plasma Coproporphyrin I and III. Journal of Pharmacology and Experimental Therapeutics, 2021, 376, 29-39. | 1.3 | 10 |
| 34 | Endogenous Plasma Kynurenic Acid in Human: A Newly Discovered Biomarker for Drug-Drug Interactions Involving Organic Anion Transporter 1 and 3 Inhibition. Drug Metabolism and Disposition, 2021, 49, 1063-1069. | 1.7 | 8 |
| 35 | A pharmaceutical industry perspective on transporter and CYP-mediated drugâ€“drug interactions: kidney transporter biomarkers. Bioanalysis, 2018, 10, 625-631. | 0.6 | 7 |
| 36 | Absence of OATP1B (Organic Anionâ€“Transporting Polypeptide) Induction by Rifampin in Cynomolgus Monkeys: Determination Using the Endogenous OATP1B Marker Coproporphyrin and Tissue Gene Expression. Journal of Pharmacology and Experimental Therapeutics, 2020, 375, 139-151. | 1.3 | 7 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Absorption and Disposition of Coproporphyrin I (CPI) in Cynomolgus Monkeys and Mice: Pharmacokinetic Evidence to Support the Use of CPI to Inform the Potential for Organic Anion-Transporting Polypeptide Inhibition. Drug Metabolism and Disposition, 2020, 48, 724-734. | 1.7 | 7 |
| 38 | Endogenous Coproporphyrin I and III are Altered in Multidrug Resistance-Associated Protein 2-Deficient (TRâ^') Rats. Journal of Pharmaceutical Sciences, 2021, 110, 404-411. | 1.6 | 7 |
| 39 | Tenofovir Disoproxil Fumarate Is Not an Inhibitor of Human Organic Cation Transporter 1. Journal of Pharmacology and Experimental Therapeutics, 2017, 360, 341-342. | 1.3 | 6 |
| 40 | In Vitro Stimulation of Multidrug Resistance-Associated Protein 2 Function Is Not Reproduced In Vivo in Rats. Pharmaceutics, 2018, 10, 125. | 2.0 | 5 |
| 41 | LCâ€“MS/MS bioanalysis of plasma 1, 14-tetradecanedioic acid and 1, 16-hexadecanedioic acid as candidate biomarkers for organic anion-transporting polypeptide mediated drugâ€“drug interactions. Bioanalysis, 2018, 10, 1473-1485. | 0.6 | 5 |
| 42 | Prediction of drugâ€“drug interaction potential mediated by transporters between dasatinib and metformin, pravastatin, and rosuvastatin using physiologically based pharmacokinetic modeling. Cancer Chemotherapy and Pharmacology, 2022, 89, 383-392. | 1.1 | 5 |
| 43 | Simultaneous measurement of mouse and human albumin in chimeric mice with humanized livers. Bioanalysis, 2022, 14, 267-278. | 0.6 | 0 |